clinical trial · NCT06885567
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
BeyondBio Inc.·phase2·not yet recruiting·n = 90
Alzheimer DiseaseAlzheimer' DiseaseBEY2153Placebo
brief summary
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.
started
Jul 1, 2025
primary completion
Jul 1, 2028
completion
Aug 1, 2028
last updated
Mar 20, 2025
official title
A Multicenter, Randomized, Double-blind, Parallel Design, Placebo-controlled, Phase 2 Clinical Trial and Open-Label Extension Study to Evaluate the Safety and Efficacy for BEY2153 in Patients with Early Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol